Xentuzumab (BI 836845), an IGF-neutralizing antibody, combined with exemestane and everolimus in hormone receptor-positive (HR plus ) locally advanced/metastatic breast cancer: Randomized Phase 2 Results

被引：0

作者：

Crown, John ^{[1
]}

Sablin, Marie-Paule ^{[2
]}

Cortes, Javier ^{[3
]}

Bergh, Jonas ^{[4
,5
]}

Im, Seock-Ah ^{[6
]}

Lu, Yen-Shen ^{[7
]}

Martinez, Noelia ^{[8
,9
]}

Neven, Patrick ^{[10
]}

Lee, Keun Seok ^{[11
]}

Morales, Serafin ^{[12
]}

Perez-Fidalgo, J. Alejandro ^{[13
,14
]}

Adamson, Douglas ^{[15
]}

Goncalves, Anthony ^{[16
]}

Prat, Aleix ^{[17
]}

Jerusalem, Guy ^{[18
]}

Schlieker, Laura ^{[19
,20
]}

Espadero, Rosa-Maria ^{[21
]}

Bogenrieder, Thomas ^{[22
]}

Huang, Dennis Chin-Lun ^{[23
]}

Schmid, Peter ^{[24
,25
]}

机构：

[1] St Vincent Univ Hosp, Dublin, Ireland

[2] Inst Curie, Paris, France

[3] Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[4] Karolinska Inst, Stockholm, Sweden

[5] Karolinska Univ Hosp, Stockholm, Sweden

[6] Seoul Natl Univ Hosp, Seoul, South Korea

[7] Natl Taiwan Univ Hosp, Taipei, Taiwan

[8] IOB Inst Oncol, Quironsalud Grp, Madrid, Spain

[9] IOB Inst Oncol, Quironsalud Grp, Barcelona, Spain

[10] UZ Leuven, Campus Gasthuisberg, Lueven, Belgium

[11] Natl Canc Ctr, Goyang, South Korea

[12] Hosp Univ Arnau Vilanova Lleida, Lleida, Spain

[13] Hosp Clin Univ Valencia, Biomed Res Inst INCLIVA, Valencia, Spain

[14] Ctr Invest Biomed Red Canc, Madrid, Spain

[15] Ninewells Hosp, Tayside Canc Ctr, Dundee, Scotland

[16] Inst Paoli Calmettes, Marseille, France

[17] Hosp Clin Barcelona, Serv Oncol Med, Barcelona, Spain

[18] Univ Liege, CHU Liege, Liege, Belgium

[19] Boehringer Ingelheim Pharma GmbH & Co KG, Bracknell, Berks, England

[20] Staburo GmbH & Co KG Staburo GmbH, Munich, Germany

[21] Boehringer Ingelheim Espana SA, Barcelona, Spain

[22] Boehringer Ingelheim RCV, Vienna, Austria

[23] Boehringer Ingelheim Taiwan Ltd, Taipei, Taiwan

[24] Barts Canc Inst, Ctr Expt Canc Med, London, England

[25] Queen Mary Univ London, London, England

来源：

BRITISH JOURNAL OF CANCER | 2019年 / 121卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：20 / 20

页数：1

共 50 条

[1] Xentuzumab (BI 836845), an IGF-neutralizing antibody, combined with exemestane and everolimus in hormone receptor-positive (HR plus ) locally advanced/metastatic breast cancer: Randomised phase 2 results
Crown, John
Sablin, Marie-Paule
Cortes, Javier
Bergh, Jonas
Im, Seock-Ah
Lu, Yen-Shen
Martinez, Noelia
Neven, Patrick
Lee, Keun Seok
Morales, Serafin
Alejandro Perez-Fidalgo, J.
Adamson, Douglas
Goncalves, Anthony
Prat, Aleix
Jerusalem, Guy
Schlieker, Laura
Espadero, Rosa-Maria
Bogenrieder, Thomas
Huang, Dennis Chin-Lun
Schmid, Peter
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 173 - 173
[2] Xentuzumab (BI 836845), an insulin-like growth factor (IGF)-neutralizing antibody (Ab), combined with exemestane and everolimus in hormone receptor-positive (HR plus ) locally advanced/metastatic breast cancer (LA/mBC): Randomized phase 2 results
Crown, J.
Sablin, M-P
Cortes, J.
Bergh, J.
Im, S-A
Lu, Y-S
Martinez, N.
Neven, P.
Lee, K. S.
Morales, S.
Perez-Fidalgo, J. A.
Adamson, D.
Goncalves, A.
Prat, A.
Jerusalem, G.
Schlieker, L.
Espadero, R-M
Bogenrieder, T.
Huang, D. Chin-Lun
Schmid, P.
CANCER RESEARCH, 2019, 79 (04)
[3] A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Schmid, Peter
Sablin, Marie-Paule
Bergh, Jonas
Im, Seock-Ah
Lu, Yen-Shen
Martinez, Noelia
Neven, Patrick
Lee, Keun Seok
Morales, Serafin
Perez-Fidalgo, J. Alejandro
Adamson, Douglas
Goncalves, Anthony
Prat, Aleix
Jerusalem, Guy
Schlieker, Laura
Espadero, Rosa-Maria
Bogenrieder, Thomas
Huang, Dennis Chin-Lun
Crown, John
Cortes, Javier
BREAST CANCER RESEARCH, 2021, 23 (01)
[4] A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Peter Schmid
Marie-Paule Sablin
Jonas Bergh
Seock-Ah Im
Yen-Shen Lu
Noelia Martínez
Patrick Neven
Keun Seok Lee
Serafín Morales
J. Alejandro Pérez-Fidalgo
Douglas Adamson
Anthony Gonçalves
Aleix Prat
Guy Jerusalem
Laura Schlieker
Rosa-Maria Espadero
Thomas Bogenrieder
Dennis Chin-Lun Huang
John Crown
Javier Cortés
Breast Cancer Research, 23
[5] Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralizing antibody, combined with exemestane (Ex) and everolimus (Ev) in hormone receptor-positive (HR plus ) locally advanced or metastatic breast cancer (BC): primary phase lb results.
Cortes, Javier
Janez, Noelia Martinez
Sablin, Marie-Paule
Perez-Fidalgo, Jose Alejandro
Neven, Patrick
Hedayati, Elham
Ballester, Alexandra
Ehrhart, Marie-Paule
Huang, Dennis C.
Bogenrieder, Thomas
Schmid, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[6] Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralising antibody, in combination with exemestane and everolimus in postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer: Preliminary results of the Phase 1b part
Cortes, J.
Martinez Janesz, N.
Sablin, M. P.
Perez-Fidalgo, J. A.
Neven, P.
Hedayati, E.
Ballester, A.
Ehrhart, M. P.
Huang, D. Chin-Lun
Bogenrieder, T.
Schmid, P.
EUROPEAN JOURNAL OF CANCER, 2016, 57 : S112 - S112
[7] Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain
E. Ciruelos
M. Vidal
E. Martínez de Dueñas
N. Martínez-Jáñez
Y. Fernández
J. A. García-Sáenz
L. Murillo
F. Carabantes
A. Beliera
R. Fonseca
J. Gavilá
Clinical and Translational Oncology, 2018, 20 : 753 - 760
[8] Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain
Ciruelos, E.
Vidal, M.
Martinez de Duenas, E.
Martinez-Janez, N.
Fernandez, Y.
Garcia-Saenz, J. A.
Murillo, L.
Carabantes, F.
Beliera, A.
Fonseca, R.
Gavila, J.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (06): : 753 - 760
[9] Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer
Ottestad, Lars
Fronth, Line
Rajendiran, Sajitha
Aksnes, Liv Hege
Eikesdal, Hans Petter
Blix, Egil Store
Ewertz, Marianne
ACTA ONCOLOGICA, 2019, 58 (03) : 385 - 387
[10] Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Lim, Bora
Potter, David A.
Salkeni, Mohamad A.
Silverman, Paula
Haddad, Tufia C.
Forget, Frederic
Awada, Ahmad
Canon, Jean-Luc
Danso, Michael
Lortholary, Alain
Bourgeois, Hugues
Tan-Chiu, Elizabeth
Vincent, Sylvie
Bahamon, Brittany
Galinsky, Kevin J.
Patel, Chirag
Neuwirth, Rachel
Leonard, E. Jane
Diamond, Jennifer R.
CLINICAL CANCER RESEARCH, 2021, 27 (12) : 3329 - 3338

← 1 2 3 4 5 →